



Dedicated To Life

May 18, 2023

Listing Department  
**BSE LIMITED**  
P J Towers, Dalal Street,  
Mumbai-400 001

**Code: 532321**

Listing Department  
**NATIONAL STOCK EXCHANGE OF INDIA LIMITED**  
Exchange Plaza, C/1, Block G,  
Bandra Kurla Complex,  
Bandra (E),  
Mumbai-400 051

**Code: ZYDUSLIFE**

Re: **Investor Presentation**

Dear Sir,

Please find attached the Investor Presentation on the audited financial results for the quarter / year ended on March 31, 2023.

Please find the same in order.

Thanking you,

Yours faithfully,  
For, **ZYDUS LIFESCIENCES LIMITED**

**DHAVAL N. SONI**  
**COMPANY SECRETARY**

Encl.: As above





# Zydus Lifesciences Limited

Earnings Presentation: Q4 and Full Year FY23

18<sup>th</sup> May, 2023

- *THIS PRESENTATION (PRESENTATION) IS NOT AN OFFER TO SELL ANY SECURITIES OR A SOLICITATION TO BUY ANY SECURITIES OF ZYDUS LIFESCIENCES LIMITED OR ITS SUBSIDIARIES OR JOINT VENTURES (TOGETHER, THE "COMPANY"). The material that follows is a Presentation of general background information about the Company's activities as at the date of the Presentation or as otherwise indicated. It is information given in summary form and does not purport to be complete and it cannot be guaranteed that such information is true and accurate. This Presentation has been prepared by and is the sole responsibility of the Company. By accessing this Presentation, you are agreeing to be bound by the trading restrictions. It is for general information purposes only and should not be considered as a recommendation that any investor should subscribe / purchase the Company shares. This Presentation includes statements that are, or may be deemed to be, "forward-looking statements". These forward-looking statements can be identified by the use of forward-looking terminology, including the terms "believes", "estimates", "anticipates", "projects", "expects", "intends", "may", "will", "seeks" or "should" or, in each case, their negative or other variations or comparable terminology, or by discussions of strategy, plans, aims, objectives, goals, future events or intentions. These forward-looking statements include all matters that are not historical facts. They appear in a number of places throughout this Presentation and include statements regarding the Company's intentions, beliefs or current expectations concerning, amongst other things, its results or operations, financial condition, liquidity, prospects, growth, strategies and the industry in which the Company operates.*
- *By their nature, forward-looking statements involve risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future. Forward-looking statements are not guarantees of future performance including those relating to general business plans and strategy of the Company, its future outlook and growth prospects, and future developments in its businesses and its competitive and regulatory environment. No representation, warranty or undertaking, express or implied, is made or assurance given that such statements, views, projections or forecasts, if any, are correct or that the objectives of the Company will be achieved. There are some important factors that could cause material differences to Company's actual results. These include (i) our ability to successfully implement our strategy (ii) our growth and expansion plans (iii) changes in regulatory norms applicable to the Company (iv) technological changes (v) investment income (vi) cash flow projections etc.*
- *The Company, as such, makes no representation or warranty, express or implied, as to, and does not accept any responsibility or liability with respect to, the fairness, accuracy, completeness or correctness of any information or opinions contained herein. The information contained in this Presentation, unless otherwise specified is only current as of the date of this Presentation. The Company assumes no responsibility to publicly amend, modify or revise any forward looking statements, on the basis of any subsequent development, information or events, or otherwise. Unless otherwise stated in this Presentation, the information contained herein is based on management information and estimates. This document is just a Presentation and is not intended to be a "prospectus" or "offer document" or a "private placement offer letter" (as defined or referred to, as the case may be, under the Companies Act, 2013). It is clarified that this Presentation is not intended to be a document offering for subscription or sale of any securities or inviting offers from the Indian public (including any section thereof) or from persons residing in any other jurisdiction including the United States for the subscription to or sale of any securities including the Company's equity shares. No part of it should form the basis of or be relied upon in connection with any investment decision or any contract or commitment to purchase or subscribe for any securities. None of the Company's securities may be offered or sold in the United States without registration under the U.S. Securities Act of 1933, as amended, except pursuant to an exemption from registration there from. This document has not been and will not be reviewed or approved by a regulatory authority in India or by any stock exchange in India. This document and its contents should not be forwarded or delivered or transmitted in any manner to any person other than its intended recipient, and should not be reproduced in any manner whatsoever.*

## Revenues from Operations\*

**Rs. 50,106 mn**  
 ↑32% YoY

## R&D

**Rs. 3,541 mn**  
 7.1% of revenues

## EBITDA & Margin %

**Rs. 12,556 mn**  
 25.1% of revenues  
 ↑75% YoY


## Net Profit ex. Exceptional

**Rs. 8,979 mn**  
 ↑126% YoY

## Highlights of Q4 FY23

- Total revenues grew **32% yoy**, led by **US formulations business**.
- **India formulations business** continued to deliver consistent performance with **12% yoy** ex-COVID growth (reported growth was 11%).
- **Consumer Wellness** business continued to maintain **leadership position** in key brands despite softer consumer demand.
- **US formulations** business continued to grow on a **sequential basis**, aided by **volume expansion** in existing products and **new launches**.
- All **major** geographies of **Emerging markets** and **Europe** business posted **strong growth**.
- EBITDA margin stood at **25.1%, up 620 bps yoy** and **260 bps qoq**.
- Net cash: Rs. 5,461 mn (at 31-Mar'23) vs Rs. 632 mn (at 31-Mar'22).
- Capex (organic) for the quarter: Rs. 2,040 mn.
- Net debt to EBITDA: (-) 0.14x (at 31-Mar'23) vs (-) 0.02x (at 31-Mar'22)

## Business-wise Sales Break-up (Rs. mn) and YoY Growth




### Note:


\* Revenues from Operations include net sales and other operating income.

# Key Financial Metrics (1/2)


## Total Revenues (Rs. mn)




## Gross Profit (Rs. mn) and Gross Margin %



## Total R&D (Rs. mn) and % to Revenues




## EBITDA ex one-offs (Rs. mn) and EBITDA Margin %




# Key Financial Metrics (2/2)


## PAT ex. Exceptional, One-offs and Discontinued ops. (Rs. mn)




## Organic Capex (Rs. mn)



## Net Debt/ EBITDA




## Net Working Capital\* (Rs. mn)




\*Net working capital includes Inventory, Trade receivables and Trade payables.

## Sustained growth momentum driven by focused execution


India Formulations Sales (Rs. mn)




Q4 FY23 Revenue Contribution



India Formulations Sales (Rs. mn)



Q4 FY23 Gr.



FY23 Gr.



## Brand building - a key growth driver

# of Brands

1000+

12

500 to 1000


23

250 to 500

38

Brand Value (Rs. Mn)\*

## Therapy-wise Break-up\*



## Highlights for the quarter

- The business **grew by 11% YoY**, ex-COVID opportunities, the **growth was 12% YoY**.
- Continued to work towards **strengthening** the presence in **focused** therapy areas.
- **Lipaglyn®** brand continued to **enhance the reach** as it **expanded** the patient base by **37%** in FY23.
- On the Super Specialty front,
  - Retained **leadership** position in **Nephrology** segment and
  - **Fastest** growing Company in **Oncology** segment.




\*Source: AWACS MAT Mar 23

## Leveraging strong brand equity to navigate through challenging times

Consumer Wellness Sales (Rs. mn)

Q4 FY23 Revenue Contribution

Consumer Wellness Sales (Rs. mn)



Q4 FY23 Gr.

YoY

11.8%

QoQ

71.7%

FY23 Gr.

12.9%

## Key brands continued to hold dominant market share

Brand Name



Market Share#

60.1%

35.4%

96.0%

6.2%

41.9%

78.4%

4.5%

Facial  
Cleansing \*

Scrub

Peel  
Off

## Highlights for the quarter

- Consumer sentiments **recovered gradually** during the quarter. However, **urban demand** remained **better** than the **rural demand**.
- Slowdown** in rural demand seems to have **bottomed out**. Expects **recovery** going forward.
- Gross margins **improved** on the back of **price increases** taken across portfolio over last few quarters and **stabilizing inflation** in key inputs except milk.
- Despite challenging macro environment, **continued to gain market share** in key brands viz. **Glucon-D**, **Nycil** and **EverYuth** (Scrub and Peel-Off).

#Source: Nielsen and IQVIA MAT March 2023 report

\* Facial cleansing segment includes Face wash, Scrub and Peel-off.






## Delivering sustained sequential growth through the year

US Formulations Sales  
(Rs. mn)

Q4 FY23 Revenue  
Contribution

US Formulations Sales  
(Rs. mn)



Q4 FY23 Gr.

YoY

58.3%

QoQ

17.0%

FY23 Gr.




28.1%

## Continued investment to build the generics pipeline

ANDA filings and approvals -  
Q4 FY23

ANDA filings and approvals -  
FY23

ANDA filings and approvals -  
Cumulative




^ includes 5 tentative approvals.

## Highlights for the quarter


- Received **28 new product approvals** (incl. 5 tentative approvals) and launched **8 new products**.  
New launches for the quarter include **Topiramate Extended Release Capsules** which was the **first generic launch** of the product.
- Filed **2 ANDAs** during the quarter.
- 78 ANDAs** pending approval with the USFDA.

## Base business continued to display robust growth


EM & EU Formulations Sales  
(Rs. mn)



Q4 FY23 Revenue  
Contribution



EM & EU Formulations  
Sales (Rs. mn)



Q4 FY23 Gr.



FY23 Gr.

9.3%

## Highlights for the quarter

- The business **grew by 34% YoY**, excluding revenue of COVID related products from the base.
- Maintained **growth momentum** on the back of **robust performance across key markets**.

## NCE: Saroglitazar Magnesium

- The molecule is undergoing Phase II(b) clinical trials for NASH indication for the US market. It received approval from the regulatory authority of Turkey to conduct clinical trials for this indication.

## NCE: ZYIL1 (NLRP3 inhibitor)

- USFDA granted an ODD status to the molecule during the quarter.

## Vaccines

- On the global development front, submitted the dossier of one of the vaccines to WHO for the purpose of pre-qualification.
- This is the second submission to WHO. Rabies vaccine has already received pre-qualification from WHO.

# Zydus at a Glance

**~\$2.15**  
bn  
Global Revenues<sup>1</sup>

**5<sup>th</sup>**  
Largest generic Co. in US  
in terms of prescription<sup>3</sup>

**7**  
R&D Centers  
For NCE, APIs, Gx formulations,  
Biosimilars and Vaccines

**>40%**  
Revenues from India  
Geography (Formulations  
and wellness)

**Among  
Top 3**  
In 65% of product  
families marketed in US<sup>4</sup>

**1<sup>st</sup>**  
Approved product for  
NASH in India - (Bilypsa<sup>®</sup> -  
Saroglitazar)

**\$6.4**  
bn  
Market Capitalization<sup>2</sup>

**12**  
Brands among Top  
300 in India<sup>5</sup>

**1<sup>st</sup>**  
OSD formulation for anemia  
associated with CKD –  
Oxemia<sup>™</sup> (Desidustat)

**36**  
Mfg. sites having  
capabilities across  
dosage forms

**23 K**  
Zydans globally incl.  
1400 scientists (R&D)

**23**  
Biosimilars in portfolio  
including 13 launched in  
India

1. In FY23, assuming exchange rate of Rs. 80.4 per USD  
2. As on 17<sup>th</sup> May, 2023, exchange rate of Rs. 82 per USD  
3. IQVIA MAT March 2023 TRx

4. IQVIA MAT March 2023 TRx  
5. As per AWACS MAT March 2023

# Consolidated Financial Performance (reported)

## Comments for Q4 FY23

- YoY growth in total income from operations was led by US formulations business.
- YoY improvement in GC margin, largely attributable to improvement in GC margin across businesses and lower base on account of COVID related inventory provision.
- YoY growth in employee benefit expenses is on account of lower base created due to gain in actuarial valuation in Q4 FY22.
- YoY growth in other operating expenses is mainly on account of lower base.

| Rs. mn   | Q4<br>FY23    | Q4<br>FY22    | YoY<br>gr.    | Q3<br>FY23    | QoQ<br>gr.    | FY23            | FY22            | YoY<br>gr.    |
|--|---------------|---------------|---------------|---------------|---------------|-----------------|-----------------|---------------|
| <b>Total Income from Ops.</b>                    | <b>50,106</b> | <b>38,056</b> | <b>31.7%</b>  | <b>42,571</b> | <b>17.7%</b>  | <b>1,72,374</b> | <b>1,51,099</b> | <b>14.1%</b>  |
| Gross Contribution (GC)                          | 33,146        | 23,098        | 43.5%         | 27,467        | 20.7%         | 1,09,273        | 95,647          | 14.2%         |
| Gross Margin %                                   | 66.2%         | 60.7%         |               | 64.5%         |               | 63.4%           | 63.3%           |               |
| Employee benefits expenses *                     | 6,507         | 5,401         | 20.5%         | 6,282         | 3.6%          | 24,827          | 21,974          | 13.0%         |
| R&D expenses                                     | 3,541         | 2,697         | 31.3%         | 3,446         | 2.8%          | 12,363          | 10,406          | 18.8%         |
| Other operating expenses                         | 9,957         | 8,405         | 18.5%         | 9,231         | 7.9%          | 36,328          | 31,413          | 15.6%         |
| Net (gain)/loss on foreign currency transactions | 585           | -582          | 200.5%        | -1,052        | 155.6%        | -2,844          | -1,553          | -83.1%        |
| <b>EBITDA</b>                                    | <b>12,556</b> | <b>7,177</b>  | <b>75.0%</b>  | <b>9,560</b>  | <b>31.3%</b>  | <b>38,599</b>   | <b>33,407</b>   | <b>15.5%</b>  |
| EBITDA Margin %                                  | 25.1%         | 18.9%         |               | 22.5%         |               | 22.4%           | 22.1%           |               |
| Other Income                                     | 378           | 791           | -52.2%        | 385           | -1.8%         | 1,866           | 2,247           | -17.0%        |
| Finance cost                                     | 277           | 385           | -28.1%        | 328           | -15.5%        | 1,299           | 1,270           | 2.3%          |
| Depreciation and amortization                    | 1,786         | 1,854         | -3.7%         | 1,816         | -1.7%         | 7,227           | 7,130           | 1.4%          |
| <b>PBT before exceptional items</b>              | <b>10,871</b> | <b>5,729</b>  | <b>89.8%</b>  | <b>7,801</b>  | <b>39.4%</b>  | <b>31,939</b>   | <b>27,254</b>   | <b>17.2%</b>  |
| Exceptional Expenses/ (Incomes)                  | 6,013         | -             |               | -             |               | 6,042           | -1,127          | 636.1%        |
| <b>Profit before Tax</b>                         | <b>4,858</b>  | <b>5,729</b>  | <b>-15.2%</b> | <b>7,801</b>  | <b>-37.7%</b> | <b>25,897</b>   | <b>28,381</b>   | <b>-8.8%</b>  |
| Tax expenses                                     | 1,372         | 1,092         | 25.6%         | 1,952         | -29.7%        | 5,878           | 5,117           | 14.9%         |
| Share of profit from JVs                         | 118           | 46            | 156.5%        | 459           | -74.3%        | 946             | 462             | 104.8%        |
| Profit/(loss) from discontinued ops. #           | -22           | -150          | 85.3%         | 4             | -650.0%       | -46             | 22,457          |               |
| Minority Interest                                | 616           | 559           | 10.2%         | 83            | 642.2%        | 1,316           | 1,310           | 0.5%          |
| <b>Reported Net Profit</b>                       | <b>2,966</b>  | <b>3,974</b>  | <b>-25.4%</b> | <b>6,229</b>  | <b>-52.4%</b> | <b>19,603</b>   | <b>44,873</b>   | <b>-56.3%</b> |

\* Excludes Research related expenses

# Profit/ (loss) from discontinued operations in FY23 refers to discontinuation of Neshor and Hercon business while in FY22, it refers to profit on divestment of India-centric Animal Health Business and discontinuation of Neshor and Hercon business.

# Details of Exchange Rate Fluctuations

| Rs. mn   | Q4<br>FY23 | Q4<br>FY22  | YoY<br>gr. %   | FY23          | FY22          | YoY<br>gr. %   |
|--|------------|-------------|----------------|---------------|---------------|----------------|
| <b>A. On operating transactions (above EBITDA line)</b>          | <b>590</b> | <b>-516</b> | <b>214.2%</b>  | <b>-3,049</b> | <b>-1,468</b> | <b>-107.7%</b> |
| a. Included in COGS  | 5          | 66          | -93%           | -205          | 85            | -341.1%        |
| b. Part of other operating expenses (shown separately)           | 585        | -582        |                | -2,844        | -1,553        |                |
|  |            |             |                |               |               |                |
| <b>B. On other income</b>  | <b>-5</b>  | <b>-200</b> | <b>97.5%</b>   | <b>-258</b>   | <b>-646</b>   | <b>60.1%</b>   |
| <b>C. On foreign currency borrowings (part of finance cost)</b>  | <b>-</b>   | <b>71</b>   | <b>-100.0%</b> | <b>1</b>      | <b>71</b>     | <b>-98.6%</b>  |
| <b>Total Exchange Rate Fluctuations ('+' = loss, '-' = gain)</b> | <b>585</b> | <b>-645</b> | <b>190.6%</b>  | <b>-3,306</b> | <b>-2,043</b> | <b>-61.8%</b>  |

# Thank you

For any queries, please contact  
Arvind Bothra  
[Arvind.Bothra@zyduslife.com](mailto:Arvind.Bothra@zyduslife.com)  
+91-22-62711905

For more information, please visit:  
 [www.zyduslife.com](http://www.zyduslife.com)

 [www.linkedin.com/company/zyduslife](http://www.linkedin.com/company/zyduslife)



## Registered Office:

Zydus Corporate Park, Scheme No. 63, Survey No. 536,  
Khoraj (Gandhinagar), Nr. Vaishnodevi Circle,  
Sarkhej-Gandhinagar Highway,  
Ahmedabad – 382 481  
Gujarat, India